| Title |
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
|
|---|---|
| Published in |
BMC Cancer, September 2012
|
| DOI | 10.1186/1471-2407-12-438 |
| Pubmed ID | |
| Authors |
Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Baños, Claus-Henning Köhne |
| Abstract |
Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report additional descriptive tolerability and quality of life data from this trial. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 68 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 17% |
| Other | 9 | 13% |
| Student > Bachelor | 8 | 11% |
| Student > Master | 5 | 7% |
| Student > Doctoral Student | 3 | 4% |
| Other | 12 | 17% |
| Unknown | 21 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 37% |
| Agricultural and Biological Sciences | 6 | 9% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Nursing and Health Professions | 3 | 4% |
| Social Sciences | 2 | 3% |
| Other | 7 | 10% |
| Unknown | 23 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 October 2012.
All research outputs
#18,316,001
of 22,679,690 outputs
Outputs from BMC Cancer
#5,415
of 8,247 outputs
Outputs of similar age
#130,681
of 172,058 outputs
Outputs of similar age from BMC Cancer
#74
of 98 outputs
Altmetric has tracked 22,679,690 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,247 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,058 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.